Cetera Investment Advisers grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 9.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 290,845 shares of the company's stock after acquiring an additional 25,307 shares during the quarter. Cetera Investment Advisers' holdings in Novo Nordisk A/S were worth $41,515,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. First PREMIER Bank purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $25,000. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth approximately $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $26,000. Orion Capital Management LLC purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $26,000. Finally, Gilliland Jeter Wealth Management LLC lifted its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock worth $26,000 after buying an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.
NVO has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, September 16th. StockNews.com upgraded Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Tuesday. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an "outperform" rating on the stock in a research report on Thursday, August 8th. Finally, Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a "buy" rating in a research report on Monday, June 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $145.17.
View Our Latest Stock Report on NVO
Shares of NYSE NVO opened at $117.95 on Wednesday. Novo Nordisk A/S has a twelve month low of $86.96 and a twelve month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $131.38 and a 200-day simple moving average of $132.77. The stock has a market capitalization of $529.30 billion, a PE ratio of 40.67, a PEG ratio of 1.35 and a beta of 0.42.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts' consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. On average, equities analysts forecast that Novo Nordisk A/S will post 3.11 earnings per share for the current year.
The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S's payout ratio is presently 24.83%.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.